TIMP1 and myeloid leukemia: Among these surrogate biomarkers, plasminogen activation inhibitor 1 and tissue inhibitor metalloproteinase 1 were moderately, positively associated with time to relapse and these proteins have been proposed as therapeutic targets for myeloid leukemia [33, 34].